MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates
: In cynomologus monkeys, systemic administration of MK‐801, a noncompetitive antagonist for the N‐methyl‐4‐aspartate receptor, prevented the development of the parkinsonian syndrome induced by the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). MK‐801 also attenuated dopamine deplet...
Gespeichert in:
| Veröffentlicht in: | Journal of neurochemistry 1992-08, Vol.59 (2), p.733-739 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 739 |
|---|---|
| container_issue | 2 |
| container_start_page | 733 |
| container_title | Journal of neurochemistry |
| container_volume | 59 |
| creator | Zuddas, Alessandro Oberto, Germano Vaglini, Francesca Fascetti, Flavia Fornai, Francesco Corsini, Giovanni U. |
| description | : In cynomologus monkeys, systemic administration of MK‐801, a noncompetitive antagonist for the N‐methyl‐4‐aspartate receptor, prevented the development of the parkinsonian syndrome induced by the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). MK‐801 also attenuated dopamine depletion in the caudate and putamen and protected dopaminergic neurons in the substantia nigra from the degeneration induced by the neurotoxin. Nevertheless, 7 days after MPTP administration in the caudate and putamen of monkeys also receiving MK‐801, the levels of toxic l‐methyl‐4‐phenylpyridinium were even higher than those measured in monkeys receiving MPTP alone. This indicates that the protective action of MK‐801 is not related to MPTP metabolism and strongly suggests that, in primates, the excitatory amino acids could play a crucial role in the mechanism of the selective neuronal death induced by MPTP. |
| doi_str_mv | 10.1111/j.1471-4159.1992.tb09429.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_1629743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16293065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4953-30779be961321de3df045b793a53e73fd2c6ddbe8d06ecf1d2c0ba292d6f312f3</originalsourceid><addsrcrecordid>eNqVkMuO0zAUhi0EGsrAIyBVCLGhDb7FqVkgjcJthhnoYlhbjn2iupM6xU5gsuMReEaeBGcalS1YsnyOz3duP0LPCM5IOq-2GeEFWXKSy4xISbOuwpJTmd3eQ7Nj6D6aYUzpkmFOH6JHMW4xJoILcoJOiKCy4GyGbq4-_f75a4XJfB3gO_guzkn6uIJuMzTJ4OmuN-DvHLKgC7YQybqGLujNYEO7H4KzzkP6PPe2N2Dnax1unI-td3E3dz5VdjvdQXyMHtS6ifBkek_R1_fvrsuPy8svH87Ls8ul4TJnad6ikBVIQRglFpitMc-rQjKdMyhYbakR1lawsliAqUnycaWppFbUjNCanaIXh7r70H7rIXZq56KBptEe2j6qcXmGRZ7A1wfQhDbGALXaj6OGQRGsRqXVVo1yqlFONSqtJqXVbUp-OnXpqx3Yv6kHaVP8-RTX0eimDtobF49Yznku7rDVAfsBVVtH48AbOFJnY9OLt7mUGGMuStfpzrW-bHvfpdSX_56a6DcT7RoY_mNTdfG5LBhjfwAmiMJx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16293065</pqid></control><display><type>article</type><title>MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates</title><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>MEDLINE</source><creator>Zuddas, Alessandro ; Oberto, Germano ; Vaglini, Francesca ; Fascetti, Flavia ; Fornai, Francesco ; Corsini, Giovanni U.</creator><creatorcontrib>Zuddas, Alessandro ; Oberto, Germano ; Vaglini, Francesca ; Fascetti, Flavia ; Fornai, Francesco ; Corsini, Giovanni U.</creatorcontrib><description>: In cynomologus monkeys, systemic administration of MK‐801, a noncompetitive antagonist for the N‐methyl‐4‐aspartate receptor, prevented the development of the parkinsonian syndrome induced by the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). MK‐801 also attenuated dopamine depletion in the caudate and putamen and protected dopaminergic neurons in the substantia nigra from the degeneration induced by the neurotoxin. Nevertheless, 7 days after MPTP administration in the caudate and putamen of monkeys also receiving MK‐801, the levels of toxic l‐methyl‐4‐phenylpyridinium were even higher than those measured in monkeys receiving MPTP alone. This indicates that the protective action of MK‐801 is not related to MPTP metabolism and strongly suggests that, in primates, the excitatory amino acids could play a crucial role in the mechanism of the selective neuronal death induced by MPTP.</description><identifier>ISSN: 0022-3042</identifier><identifier>EISSN: 1471-4159</identifier><identifier>DOI: 10.1111/j.1471-4159.1992.tb09429.x</identifier><identifier>PMID: 1629743</identifier><identifier>CODEN: JONRA9</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - adverse effects ; 1-Methyl-4-phenylpyridinium - metabolism ; 1‐Methyl‐4‐phenylpyridinium ; Animals ; Biochemistry & Molecular Biology ; Biological and medical sciences ; Caudate Nucleus - drug effects ; Disease Models, Animal ; Dizocilpine Maleate - pharmacology ; Dopamine ; Dopamine - metabolism ; Dose-Response Relationship, Drug ; Excitatory amino acids ; Life Sciences & Biomedicine ; Macaca fascicularis ; Male ; Medical sciences ; MK‐801‐1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine ; Nerve Degeneration - drug effects ; Nervous system involvement in other diseases. Miscellaneous ; Neurology ; Neurons - drug effects ; Neurosciences ; Neurosciences & Neurology ; Parkinson Disease, Secondary - chemically induced ; Parkinson Disease, Secondary - metabolism ; Parkinson Disease, Secondary - prevention & control ; Parkinsonism ; Putamen - drug effects ; Science & Technology ; Substantia Nigra - drug effects ; Substantia nigra degeneration</subject><ispartof>Journal of neurochemistry, 1992-08, Vol.59 (2), p.733-739</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>151</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wosA1992JD59900046</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c4953-30779be961321de3df045b793a53e73fd2c6ddbe8d06ecf1d2c0ba292d6f312f3</citedby><cites>FETCH-LOGICAL-c4953-30779be961321de3df045b793a53e73fd2c6ddbe8d06ecf1d2c0ba292d6f312f3</cites><orcidid>0000-0002-3883-5084</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1471-4159.1992.tb09429.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1471-4159.1992.tb09429.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27201,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5445643$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1629743$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zuddas, Alessandro</creatorcontrib><creatorcontrib>Oberto, Germano</creatorcontrib><creatorcontrib>Vaglini, Francesca</creatorcontrib><creatorcontrib>Fascetti, Flavia</creatorcontrib><creatorcontrib>Fornai, Francesco</creatorcontrib><creatorcontrib>Corsini, Giovanni U.</creatorcontrib><title>MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates</title><title>Journal of neurochemistry</title><addtitle>J NEUROCHEM</addtitle><addtitle>J Neurochem</addtitle><description>: In cynomologus monkeys, systemic administration of MK‐801, a noncompetitive antagonist for the N‐methyl‐4‐aspartate receptor, prevented the development of the parkinsonian syndrome induced by the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). MK‐801 also attenuated dopamine depletion in the caudate and putamen and protected dopaminergic neurons in the substantia nigra from the degeneration induced by the neurotoxin. Nevertheless, 7 days after MPTP administration in the caudate and putamen of monkeys also receiving MK‐801, the levels of toxic l‐methyl‐4‐phenylpyridinium were even higher than those measured in monkeys receiving MPTP alone. This indicates that the protective action of MK‐801 is not related to MPTP metabolism and strongly suggests that, in primates, the excitatory amino acids could play a crucial role in the mechanism of the selective neuronal death induced by MPTP.</description><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - adverse effects</subject><subject>1-Methyl-4-phenylpyridinium - metabolism</subject><subject>1‐Methyl‐4‐phenylpyridinium</subject><subject>Animals</subject><subject>Biochemistry & Molecular Biology</subject><subject>Biological and medical sciences</subject><subject>Caudate Nucleus - drug effects</subject><subject>Disease Models, Animal</subject><subject>Dizocilpine Maleate - pharmacology</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Excitatory amino acids</subject><subject>Life Sciences & Biomedicine</subject><subject>Macaca fascicularis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>MK‐801‐1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</subject><subject>Nerve Degeneration - drug effects</subject><subject>Nervous system involvement in other diseases. Miscellaneous</subject><subject>Neurology</subject><subject>Neurons - drug effects</subject><subject>Neurosciences</subject><subject>Neurosciences & Neurology</subject><subject>Parkinson Disease, Secondary - chemically induced</subject><subject>Parkinson Disease, Secondary - metabolism</subject><subject>Parkinson Disease, Secondary - prevention & control</subject><subject>Parkinsonism</subject><subject>Putamen - drug effects</subject><subject>Science & Technology</subject><subject>Substantia Nigra - drug effects</subject><subject>Substantia nigra degeneration</subject><issn>0022-3042</issn><issn>1471-4159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EZCTM</sourceid><sourceid>EIF</sourceid><recordid>eNqVkMuO0zAUhi0EGsrAIyBVCLGhDb7FqVkgjcJthhnoYlhbjn2iupM6xU5gsuMReEaeBGcalS1YsnyOz3duP0LPCM5IOq-2GeEFWXKSy4xISbOuwpJTmd3eQ7Nj6D6aYUzpkmFOH6JHMW4xJoILcoJOiKCy4GyGbq4-_f75a4XJfB3gO_guzkn6uIJuMzTJ4OmuN-DvHLKgC7YQybqGLujNYEO7H4KzzkP6PPe2N2Dnax1unI-td3E3dz5VdjvdQXyMHtS6ifBkek_R1_fvrsuPy8svH87Ls8ul4TJnad6ikBVIQRglFpitMc-rQjKdMyhYbakR1lawsliAqUnycaWppFbUjNCanaIXh7r70H7rIXZq56KBptEe2j6qcXmGRZ7A1wfQhDbGALXaj6OGQRGsRqXVVo1yqlFONSqtJqXVbUp-OnXpqx3Yv6kHaVP8-RTX0eimDtobF49Yznku7rDVAfsBVVtH48AbOFJnY9OLt7mUGGMuStfpzrW-bHvfpdSX_56a6DcT7RoY_mNTdfG5LBhjfwAmiMJx</recordid><startdate>199208</startdate><enddate>199208</enddate><creator>Zuddas, Alessandro</creator><creator>Oberto, Germano</creator><creator>Vaglini, Francesca</creator><creator>Fascetti, Flavia</creator><creator>Fornai, Francesco</creator><creator>Corsini, Giovanni U.</creator><general>Blackwell Publishing Ltd</general><general>Lippincott Williams & Wilkins</general><general>Blackwell</general><scope>BLEPL</scope><scope>DTL</scope><scope>EZCTM</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><orcidid>https://orcid.org/0000-0002-3883-5084</orcidid></search><sort><creationdate>199208</creationdate><title>MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates</title><author>Zuddas, Alessandro ; Oberto, Germano ; Vaglini, Francesca ; Fascetti, Flavia ; Fornai, Francesco ; Corsini, Giovanni U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4953-30779be961321de3df045b793a53e73fd2c6ddbe8d06ecf1d2c0ba292d6f312f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - adverse effects</topic><topic>1-Methyl-4-phenylpyridinium - metabolism</topic><topic>1‐Methyl‐4‐phenylpyridinium</topic><topic>Animals</topic><topic>Biochemistry & Molecular Biology</topic><topic>Biological and medical sciences</topic><topic>Caudate Nucleus - drug effects</topic><topic>Disease Models, Animal</topic><topic>Dizocilpine Maleate - pharmacology</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Excitatory amino acids</topic><topic>Life Sciences & Biomedicine</topic><topic>Macaca fascicularis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>MK‐801‐1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</topic><topic>Nerve Degeneration - drug effects</topic><topic>Nervous system involvement in other diseases. Miscellaneous</topic><topic>Neurology</topic><topic>Neurons - drug effects</topic><topic>Neurosciences</topic><topic>Neurosciences & Neurology</topic><topic>Parkinson Disease, Secondary - chemically induced</topic><topic>Parkinson Disease, Secondary - metabolism</topic><topic>Parkinson Disease, Secondary - prevention & control</topic><topic>Parkinsonism</topic><topic>Putamen - drug effects</topic><topic>Science & Technology</topic><topic>Substantia Nigra - drug effects</topic><topic>Substantia nigra degeneration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zuddas, Alessandro</creatorcontrib><creatorcontrib>Oberto, Germano</creatorcontrib><creatorcontrib>Vaglini, Francesca</creatorcontrib><creatorcontrib>Fascetti, Flavia</creatorcontrib><creatorcontrib>Fornai, Francesco</creatorcontrib><creatorcontrib>Corsini, Giovanni U.</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 1992</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of neurochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zuddas, Alessandro</au><au>Oberto, Germano</au><au>Vaglini, Francesca</au><au>Fascetti, Flavia</au><au>Fornai, Francesco</au><au>Corsini, Giovanni U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates</atitle><jtitle>Journal of neurochemistry</jtitle><stitle>J NEUROCHEM</stitle><addtitle>J Neurochem</addtitle><date>1992-08</date><risdate>1992</risdate><volume>59</volume><issue>2</issue><spage>733</spage><epage>739</epage><pages>733-739</pages><issn>0022-3042</issn><eissn>1471-4159</eissn><coden>JONRA9</coden><abstract>: In cynomologus monkeys, systemic administration of MK‐801, a noncompetitive antagonist for the N‐methyl‐4‐aspartate receptor, prevented the development of the parkinsonian syndrome induced by the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). MK‐801 also attenuated dopamine depletion in the caudate and putamen and protected dopaminergic neurons in the substantia nigra from the degeneration induced by the neurotoxin. Nevertheless, 7 days after MPTP administration in the caudate and putamen of monkeys also receiving MK‐801, the levels of toxic l‐methyl‐4‐phenylpyridinium were even higher than those measured in monkeys receiving MPTP alone. This indicates that the protective action of MK‐801 is not related to MPTP metabolism and strongly suggests that, in primates, the excitatory amino acids could play a crucial role in the mechanism of the selective neuronal death induced by MPTP.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>1629743</pmid><doi>10.1111/j.1471-4159.1992.tb09429.x</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3883-5084</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3042 |
| ispartof | Journal of neurochemistry, 1992-08, Vol.59 (2), p.733-739 |
| issn | 0022-3042 1471-4159 |
| language | eng |
| recordid | cdi_pubmed_primary_1629743 |
| source | Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; MEDLINE |
| subjects | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - adverse effects 1-Methyl-4-phenylpyridinium - metabolism 1‐Methyl‐4‐phenylpyridinium Animals Biochemistry & Molecular Biology Biological and medical sciences Caudate Nucleus - drug effects Disease Models, Animal Dizocilpine Maleate - pharmacology Dopamine Dopamine - metabolism Dose-Response Relationship, Drug Excitatory amino acids Life Sciences & Biomedicine Macaca fascicularis Male Medical sciences MK‐801‐1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Nerve Degeneration - drug effects Nervous system involvement in other diseases. Miscellaneous Neurology Neurons - drug effects Neurosciences Neurosciences & Neurology Parkinson Disease, Secondary - chemically induced Parkinson Disease, Secondary - metabolism Parkinson Disease, Secondary - prevention & control Parkinsonism Putamen - drug effects Science & Technology Substantia Nigra - drug effects Substantia nigra degeneration |
| title | MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T22%3A52%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MK%E2%80%90801%20Prevents%201%E2%80%90Methyl%E2%80%904%E2%80%90Phenyl%E2%80%901,2,3,6%E2%80%90Tetrahydropyridine%E2%80%90Induced%20Parkinsonism%20in%20Primates&rft.jtitle=Journal%20of%20neurochemistry&rft.au=Zuddas,%20Alessandro&rft.date=1992-08&rft.volume=59&rft.issue=2&rft.spage=733&rft.epage=739&rft.pages=733-739&rft.issn=0022-3042&rft.eissn=1471-4159&rft.coden=JONRA9&rft_id=info:doi/10.1111/j.1471-4159.1992.tb09429.x&rft_dat=%3Cproquest_pubme%3E16293065%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16293065&rft_id=info:pmid/1629743&rfr_iscdi=true |